Weekly Recap: FDA request trims CMPX ~30% and COMPANION-002 shows ORR/PFS
Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) plunged ~30%, wiping out about $104M after the FDA sought more survival data for tovecimig's BLA, even as Phase 2/3 COMPANION-002 showed higher ORR and longer PFS for tovecimig+paclitaxel and the StitchMabs platform advances its bispecific pipeline…